$KYTX

Kyverna Therapeutics, Inc.

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. Its lead product candidate, mivocabtagene autoleucel, or miv-cel, also known as KYV-101, is an autologous CD19-targeting CAR T-cell therapy. Kyverna is advancing miv-cel for stiff person syndrome and generalized myasthenia gravis, and is evaluating it in other autoimmune conditions, including progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis and systemic sclerosis. Its pipeline also includes KYV-102, a proprietary whole blood, rapid manufacturing process. Kyverna’s work includes clinical development, manufacturing and clinical-trial activities. It is conducting a Phase 3 portion of its KYSA-6 trial of miv-cel in generalized myasthenia gravis and plans to seek FDA approval for miv-cel in stiff person syndrome. Its headquarters are in Emeryville, California.

No enriched coverage for $KYTX in the last 7 days.

No SEC Form 4 filings for $KYTX in the last 30 days.

See all $KYTX insider activity →
Low

Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings

Arrowhead Pharmaceuticals (ARWR) is preparing for a Q2 2026 launch of Redemplo in severe hypertriglyceridemia (sHTG), despite Ionis Pharmaceuticals' (IONS) disappointing sales of Tryngolza. Kyverna Therapeutics (KYV) deprioritized KYV-102, focusing on miv-cel for stiff-person syndrome. Prime Medicine (PRME) advances PM577a in Wilson’s disease and PM647 in AATD. Cullinan Therapeutics (CGEN) awaits data from CLN-978 and CLN-049 trials.

Kyverna completes BLA submission for autoimmune CAR-T therapy

Kyverna Therapeutics (NASDAQ:KYTX) submitted a Biologics License Application for miv-cel in stiff person syndrome, seeking priority review. The company reported a Q3 2026 net loss of $41.9 million and $170.6 million in cash. It expects operating runway into 2028 and is focusing on late-stage neurologic indications with miv-cel.

Kyverna Therapeutics 3Q 2026: EPS ($0.68) — 10-Q Summary

Kyverna Therapeutics reported a 14% wider net loss YoY in 3Q 2026, with total operating expenses rising 11%. R&D expenses fell 11%, while general and administrative expenses increased 92%. The company completed a rolling BLA submission for miv-cel in SPS and expects to finish patient enrollment in a Phase 3 trial by mid-2027.

KYTX sentiment & insider activity

Recent KYTX coverage spans financial news, earnings and regulation.

What's driving KYTX

AlphAI scores every news story that mentions KYTX with an AI model for sentiment and relevance, and aggregates insider trades from Kyverna Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $KYTX

Score

Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings

Arrowhead Pharmaceuticals (ARWR) is preparing for a Q2 2026 launch of Redemplo in severe hypertriglyceridemia (sHTG), despite Ionis Pharmaceuticals' (IONS) disappointing sales of Tryngolza. Kyverna Therapeutics (KYV) deprioritized KYV-102, focusing on miv-cel for stiff-person syndrome. Prime Medicine (PRME) advances PM577a in Wilson’s disease and PM647 in AATD. Cullinan Therapeutics (CGEN) awaits data from CLN-978 and CLN-049 trials.

Kyverna Therapeutics 3Q 2026: EPS ($0.68) — 10-Q Summary

Kyverna Therapeutics reported a 14% wider net loss YoY in 3Q 2026, with total operating expenses rising 11%. R&D expenses fell 11%, while general and administrative expenses increased 92%. The company completed a rolling BLA submission for miv-cel in SPS and expects to finish patient enrollment in a Phase 3 trial by mid-2027.

$KYTXMedAI 8/10Earnings

Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results

Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results BLA submission for miv-cel in SPS completed with request for priority review Commercial readiness advancing for potential

$KYTXMedAI 8/10

A patient with progressive MS had sustained clinical benefit beyond two years after one dose.

Kyverna Therapeutics (KYTX) reported promising Phase 1 trial data for miv-cel in progressive multiple sclerosis, showing sustained clinical benefits and robust CAR T-cell penetration in the CNS. The treatment demonstrated a well-tolerated safety profile and received RMAT designation for non-active secondary progressive MS, with a development update expected by early 2027.

$KYTXHighAI 9/10

Kyverna Therapeutics, Inc. (KYTX) Reports 1-Year Registrational Data Showing Sustained Benefit in SPS

Kyverna Therapeutics (KYTX) reported 1-year data from its KYSA-8 trial, showing sustained clinical benefit and deep B-cell depletion with miv-cel in stiff person syndrome. The treatment had a well-tolerated safety profile, with no high-grade CRS or ICANS reported. The data confirms earlier signals of efficacy and safety, with potential for FDA review and approval.

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Kyverna Therapeutics (KYTX) will present data at MSToronto2026 showing sustained benefits and a well-tolerated safety profile for its CAR T-cell therapy, miv-cel, in stiff person syndrome and progressive multiple sclerosis. The company expects to complete its BLA submission for SPS this quarter, potentially leading to the first approved treatment for the condition.

$KYTXHighAI 8/10

Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Kyverna Therapeutics advances in autoimmune CAR T therapy despite setbacks at Novartis and Bristol Myers Squibb. Novartis paused trials after patient deaths, and BMS halted trials due to safety concerns. Kyverna's mivocabtagene autoleucel (miv-cel) shows promise in stiff person syndrome with a solid safety profile. The company aims to complete a BLA filing by year-end.

Related tickers